NEW YORK (GenomeWeb News) – Fluidigm and NanoString Technologies have settled lawsuits filed by Fluidigm that accused NanoString of false advertising, unfair competition, and unlawful trade practice, the companies announced after the close of the market on Tuesday.

As part of the settlement, NanoString is required to remove all references to a single-cell comparison study of Fluidigm's and NanoString's single-cell products, and to recall and destroy all materials related to and/or based on the study, Fluidigm said.

Financial terms of the settlement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.